Viatris Inc. has reported its financial results for the fourth quarter and full year of 2025, and the figures indicate a strong performance. The company's total revenues for the fourth quarter reached $3.7 billion, showing a 5% increase compared to the same period in 2024. For the full year 2025, Viatris recorded total revenues of $14.3 billion.
In terms of net sales, the company achieved $3.69 billion in the fourth quarter, a 5% increase from the previous year. Notably, Viatris saw growth in both developed and emerging markets, with developed markets reaching $2.25 billion and emerging markets hitting $564.7 million. The net sales in Greater China alone amounted to $572.9 million, indicating a 10% increase from the previous year.
Breaking down the net sales by product category, Viatris reported $2.35 billion from brands, marking an 8% increase, while generics brought in $1.34 billion, showing no change from the previous year.
In terms of profitability, the company reported a U.S. GAAP gross profit of $1.15 billion with a gross margin of 31%, and an adjusted gross profit of $2.10 billion with a 56.8% gross margin. The U.S. GAAP net loss was recorded at $340.1 million, and the U.S. GAAP loss per share was $0.30. On an adjusted basis, Viatris achieved net earnings of $658.7 million, translating to an adjusted EPS of $0.57, marking a 6% increase from the previous year.
Furthermore, the company reported EBITDA of $543.4 million, reflecting a significant 60% increase from the same period in 2024. The adjusted EBITDA reached $1.00 billion, indicating a 2% increase. Viatris also demonstrated strong cash generation, with U.S. GAAP net cash provided by operating activities reaching $815.8 million, representing a substantial 69% increase from the previous year.
Additionally, the company returned over $1 billion to shareholders in 2025 and expects to continue with a balanced capital allocation approach for 2026. Viatris also completed an enterprise-wide strategic review and anticipates delivering $650 million in total cost savings while reinvesting up to $250 million over the next three years.
Looking ahead to 2026, Viatris provided financial guidance and expressed confidence in its position for sustainable growth. The company also expects regulatory decisions for six product candidates in 2026 and multiple important pipeline milestones.
Today the company's shares have moved 0.16% to a price of $12.86. Check out the company's full 8-K submission here.
